PT - JOURNAL ARTICLE AU - AGATA JARZĄB AU - JAROGNIEW ŁUSZCZKI AU - MAŁGORZATA GUZ AU - KRYSTYNA SKALICKA-WOŹNIAK AU - MARTA HAŁASA AU - JOLANTA SMOK-KALWAT AU - KRZYSZTOF POLBERG AU - ANDRZEJ STEPULAK TI - Combination of Osthole and Cisplatin Against Rhabdomyosarcoma TE671 Cells Yielded Additive Pharmacologic Interaction by Means of Isobolographic Analysis DP - 2018 Jan 01 TA - Anticancer Research PG - 205--210 VI - 38 IP - 1 4099 - http://ar.iiarjournals.org/content/38/1/205.short 4100 - http://ar.iiarjournals.org/content/38/1/205.full SO - Anticancer Res2018 Jan 01; 38 AB - Background/Aim: Osthole is a simple coumarin that has been found to have anticancer, anti-inflammatory, antiviral, anticoagulant, anticonvulsant and antiallergic activities. The aim of this study was to analyze the combined anti-proliferative effect of cisplatin (CDDP) and osthole on a rhabdomyosarcoma cell line, and assess the pharmacology of drug-drug interaction between these drugs using isobolographic analysis. Materials and Methods: The anticancer actions of osthole in combination with CDDP were evaluated using the tetrazolium dye-based MTT cell proliferation assay. Results: Osthole and CDDP applied together augmented their anti-cancer activities and yielded an additive type of pharmacologic interaction by means of isobolographic analysis. Conclusion: Combined therapy using osthole and cisplatin could be suggested as a potential chemotherapy regimen against rhabdomyosarcoma.